Results 11 to 20 of about 109,705 (362)

Sutimlimab in Cold Agglutinin Disease

New England Journal of Medicine, 2021
Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.We conducted a 26-week multicenter, open-label ...
Röth, Alexander, Barcellini, Wilma, D’Sa, Shirley, Miyakawa, Yoshitaka, Broome, Catherine M., Michel, Marc, Kuter, David J., Jilma, Bernd, Tvedt, Tor H.A., Frübis, Joachim, Jiang, Xiaoyu, Lin, Stella, Reuter, Caroline, Morales-Arias, Jaime, Hobbs, William, Berentsen, Sigbjørn   +15 more
openaire   +4 more sources

Cold agglutinin disease [PDF]

Hematology, 2016
AbstractPrimary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a specific, clonal lymphoproliferative B-cell bone marrow disorder results in autoimmune hemolytic anemia. The immune hemolysis is entirely complement-dependent, predominantly mediated by activation of the classical pathway and phagocytosis of ...
S. Berentsen
openaire   +4 more sources

Llama-Derived Single Domain Antibodies Specific for Abrus Agglutinin

Toxins, 2011
Llama derived single domain antibodies (sdAb), the recombinantly expressed variable heavy domains from the unique heavy-chain only antibodies of camelids, were isolated from a library derived from llamas immunized with a commercial abrin toxoid ...
James P. Carney, Rachael Bernstein, Eric A. E. Garber, Jennifer L. Walker, Thomas W. O’Brien, Alena Calm, Jinny L. Liu, Ellen R. Goldman, Scott Walper, Dan Zabetakis, George P. Anderson   +10 more
doaj   +2 more sources

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Blood, 2022
Röth and colleagues present results of a phase 3 trial of the C1s classical complement pathway inhibitor sutimlimab for the treatment of patients with cold agglutinin disease (CAD) who did not receive a transfusion within the previous 6 months.
A. Röth, S. Berentsen, W. Barcellini, S. D’Sa, B. Jilma, M. Michel, I. Weitz, M. Yamaguchi, J. Nishimura, J. Vos, M. Storek, N. Wong, Parija Patel, Xiaoyu Jiang, D. Vagge, M. Wardȩcki, F. Shafer, Michelle Lee, C. Broome   +18 more
semanticscholar   +1 more source

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?

Immunotherapy, 2022
Therapies for cold agglutinin disease have been directed at the pathogenic B-cell clone. Sutimlimab, a monoclonal antibody that targets C1s, is the first complement inhibitor to be extensively studied in cold agglutinin disease.
S. Berentsen, W. Barcellini, S. D’Sa, B. Jilma   +3 more
semanticscholar   +1 more source

How I Treat Cold Agglutinin Disease.

Blood, 2021
The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience.
S. Berentsen
semanticscholar   +1 more source

New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia

Frontiers in Immunology, 2020
Autoimmune hemolytic anemias mediated by cold agglutinins can be divided into cold agglutinin disease (CAD), which is a well-defined clinicopathologic entity and a clonal lymphoproliferative disorder, and secondary cold agglutinin syndrome (CAS), in ...
S. Berentsen
semanticscholar   +1 more source

Cold agglutinin disease revisited: A multinational, observational study of 232 patients.

Blood, 2020
We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in five countries. In Norway and a northern region of Italy, the study was close to being population-based.
S. Berentsen, W. Barcellini, S. D’Sa, Ulla Randen, T. Tvedt, B. Fattizzo, E. Haukås, Megan E Kell, Robert Brudevold, A. Dahm, J. Dalgaard, H. Frøen, R. F. Hallstensen, Pernille H. Jæger, H. Hjorth-Hansen, A. Małecka, M. Oksman, J. Rolke, M. Sekhar, J. H. Sørbø, E. Tjønnfjord, G. Tsykunova, G. Tjønnfjord   +22 more
semanticscholar   +1 more source

Increased risk of thrombotic events in cold agglutinin disease: A 10‐year retrospective analysis

Research and Practice in Thrombosis and Haemostasis, 2020
Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia mediated by IgM autoantibodies that trigger hemolysis via classical complement pathway.
C. Broome, J. Cunningham, M. Mullins, Xiaohui Jiang, L. Bylsma, J. Fryzek, A. Rosenthal   +6 more
semanticscholar   +1 more source

Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID‐19)

British Journal of Haematology, 2020
Cold agglutinin syndrome (CAS) is a rare disorder associated with infection, autoimmune disorders, and lymphoid malignancies. We are present a case of CAS associated with SARS-CoV-2 that causes COVID-19.
Emily Zagorski, T. Pawar, Shoja Rahimian, D. Forman   +3 more
semanticscholar   +1 more source